Athira Pharma (ATHA) News Today → Read this before you buy AI stocks (From InvestorPlace) (Ad) Free ATHA Stock Alerts $2.52 0.00 (0.00%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 10:49 AM | markets.businessinsider.comBuy Rating Affirmed on Athira Pharma Amid Promising Alzheimer’s Drug Developments and Strategic AdvancementsMay 18 at 5:21 AM | americanbankingnews.comJMP Securities Reiterates "Market Outperform" Rating for Athira Pharma (NASDAQ:ATHA)May 17 at 5:00 PM | globenewswire.comAthira Pharma Announces Proposed Settlement of Stockholder Derivative ActionMay 17 at 7:35 AM | bizjournals.comAthira names new chief medical officer ahead of release of key trial dataMay 16, 2024 | marketbeat.comAthira Pharma (NASDAQ:ATHA) Rating Reiterated by JMP SecuritiesJMP Securities reiterated a "market outperform" rating and issued a $19.00 target price on shares of Athira Pharma in a report on Thursday.May 16, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesMay 16, 2024 | marketbeat.comAthira Pharma (NASDAQ:ATHA) Posts Earnings Results, Beats Expectations By $0.11 EPSAthira Pharma (NASDAQ:ATHA - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.11.May 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Celcuity (CELC) and ATAI Life Sciences (ATAI)May 16, 2024 | msn.comATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024May 15, 2024 | globenewswire.comAthira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesMay 2, 2024 | globenewswire.comAthira Pharma to Participate in Upcoming May ConferencesApril 27, 2024 | seekingalpha.comATHA Athira Pharma, Inc.April 23, 2024 | finance.yahoo.comOne Athira Pharma Insider Raised Their Stake In The Previous YearApril 17, 2024 | msn.comAthira Pharma (ATHA) Price Target Increased by 7.49% to 7.57April 15, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerApril 15, 2024 | markets.businessinsider.comAthira Pharma Appoints Javier San Martin As New Chief Medical OfficerApril 15, 2024 | globenewswire.comAthira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerApril 11, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's DiseaseApril 11, 2024 | finance.yahoo.comAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseApril 11, 2024 | globenewswire.comAthira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's DiseaseApril 3, 2024 | globenewswire.comAthira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual MeetingMarch 20, 2024 | finance.yahoo.comAthira Pharma, Inc. (ATHA)March 15, 2024 | marketbeat.comShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Increases By 20.5%Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 783,600 shares, an increase of 20.5% from the February 14th total of 650,300 shares. Approximately 2.2% of the company's shares are short sold. Based on an average trading volume of 394,600 shares, the short-interest ratio is currently 2.0 days.March 8, 2024 | finance.yahoo.comAthira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International ConferenceMarch 8, 2024 | globenewswire.comAthira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International ConferenceMarch 3, 2024 | marketbeat.comShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Drops By 9.4%Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 650,300 shares, a decline of 9.4% from the January 31st total of 717,600 shares. Based on an average daily trading volume, of 344,300 shares, the short-interest ratio is presently 1.9 days. Currently, 1.8% of the company's stock are sold short.February 25, 2024 | marketbeat.comNan Fung Group Holdings Ltd Purchases 168,231 Shares of Athira Pharma, Inc. (NASDAQ:ATHA)Nan Fung Group Holdings Ltd raised its position in Athira Pharma, Inc. (NASDAQ:ATHA - Free Report) by 1,429.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 180,000 shares of the company's stock after purchasing an additFebruary 23, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business UpdatesFebruary 22, 2024 | globenewswire.comAthira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business UpdatesFebruary 22, 2024 | marketbeat.comBarclays PLC Raises Holdings in Athira Pharma, Inc. (NASDAQ:ATHA)Barclays PLC boosted its stake in shares of Athira Pharma, Inc. (NASDAQ:ATHA - Free Report) by 99.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 435,841 shares of the company's stock after acquiring an additional 216,933February 13, 2024 | marketbeat.comAthira Pharma, Inc. (NASDAQ:ATHA) Sees Significant Increase in Short InterestAthira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 717,600 shares, a growth of 39.6% from the January 15th total of 513,900 shares. Approximately 2.1% of the shares of the stock are short sold. Based on an average daily volume of 331,300 shares, the short-interest ratio is currently 2.2 days.February 8, 2024 | finance.yahoo.comAthira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)February 6, 2024 | uk.investing.comAthira Pharma Inc (ATHA)January 28, 2024 | marketbeat.comShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Grows By 25.4%Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 513,900 shares, a growth of 25.4% from the December 31st total of 409,900 shares. Currently, 1.5% of the company's shares are short sold. Based on an average trading volume of 331,500 shares, the short-interest ratio is presently 1.6 days.January 22, 2024 | finance.yahoo.comWith 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investorsJanuary 15, 2024 | marketbeat.comAthira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 16.6% in DecemberAthira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 409,900 shares, a drop of 16.6% from the December 15th total of 491,600 shares. Based on an average trading volume of 292,800 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.2% of the shares of the stock are short sold.January 11, 2024 | markets.businessinsider.comAthira Pharma: A Buy Rating Backed by Promising Alzheimer’s Drug Prospects and Strong Cash PositionJanuary 10, 2024 | bizjournals.comAthira Pharma's chief medical officer retiresJanuary 8, 2024 | marketbeat.comMark James Litton Sells 4,820 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) StockAthira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) CEO Mark James Litton sold 4,820 shares of the firm's stock in a transaction on Friday, January 5th. The stock was sold at an average price of $2.91, for a total value of $14,026.20. Following the sale, the chief executive officer now directly owns 144,397 shares of the company's stock, valued at approximately $420,195.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 8, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Athira Pharma (ATHA)January 8, 2024 | finance.yahoo.comAthira Pharma Provides 2024 Clinical Pipeline Outlook and Business UpdateJanuary 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Athira Pharma as LIFT-AD Trial Progresses with Promising Prospects and Solid Financial StandingJanuary 3, 2024 | finanznachrichten.deAthira Pharma, Inc.: Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's DiseaseJanuary 2, 2024 | msn.comAthira Pharma 10% owner Perceptive Advisors discloses purchase of 605,686 sharesDecember 25, 2023 | benzinga.comAthira Pharma Stock (NASDAQ:ATHA) Dividends: History, Yield and DatesDecember 15, 2023 | markets.businessinsider.comOptimistic Outlook for Athira Pharma Despite Setback: Buy Rating AffirmedDecember 13, 2023 | markets.businessinsider.comBuy Rating for Athira Pharma Backed by Promising Fosgonimeton Trial Results and Favorable Safety ProfileDecember 12, 2023 | finance.yahoo.comAthira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy BodiesDecember 1, 2023 | marketbeat.comThese biotechs targeting multiple neurodegenerative diseases (ATHA)A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.November 29, 2023 | finance.yahoo.comAthira Pharma to Participate in Sidoti December Small Cap Investor Conference Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some ATHA Media Mentions By Week ATHA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHA News Sentiment▼0.500.42▲Average Medical News Sentiment ATHA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHA Articles This Week▼121▲ATHA Articles Average Week Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PLX News Today CVM News Today CGTX News Today ALVR News Today DTIL News Today TIL News Today ATRA News Today CRIS News Today ELUT News Today TSBX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe #1 Crypto for AIWeiss Ratings**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
